20.10.2015 13:54:18
|
RXi Pharma Reports Positive Results With Its RNAi Platform - Quick Facts
(RTTNews) - RXi Pharmaceuticals Corp. (RXII) reported positive results from a collaboration with Biogazelle NV, a company with a longstanding track record and internationally recognized expertise in RNA gene expression analysis. RXi Pharma said, specifically-designed sd-rxRNAs based on RXi's proprietary, self-delivering RNAi platform demonstrated robust and potent reduction of the levels of lncRNAs in a target specific manner. The company said these findings expand the number of potential genes RXi is capable of targeting by approximately four fold.
Geert Cauwenbergh, CEO of RXi Pharma, said: "These results constitute a major boost to the value of our self-delivering platform by significantly expanding the breadth of therapeutic targets we can now pursue. This opens up additional business development and partnering opportunities with our sd-rxRNA platform, further supporting RXi's initiatives to build shareholder value."
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu RXi Pharmaceuticals Corpmehr Nachrichten
Keine Nachrichten verfügbar. |